<DOC>
	<DOCNO>NCT01269684</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability immediate conversion Tacrolimus everolimus stable renal allograft recipient . Interest develop CNI-free regimen use agent proliferation signal inhibitor everolimus .</brief_summary>
	<brief_title>Immediate Conversion From Tacrolimus Everolimus Stable Maintenance Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criterion Primary secondary renal transplantation past 1236 month . Current immunosuppressive therapy consist Tacrolimus together MMF +/corticosteroids . Moderately impaired renal function Exclusion criterion Multiorgan recipients previous transplantation organ kidney . Acute rejection episode last 6 month . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney</keyword>
	<keyword>renal</keyword>
	<keyword>transplantation</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>everolimus</keyword>
	<keyword>stable allograft recipient</keyword>
</DOC>